A retrospective study to compare long-term treatment outcomes and identify predictors of response and survival in myelofibrosis patients treated on JAK2 inhibitors
Latest Information Update: 27 Jan 2023
At a glance
- Drugs BMS 911543 (Primary) ; Fedratinib (Primary) ; Momelotinib (Primary) ; Ruxolitinib (Primary) ; Janus kinase 2 inhibitors
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 27 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition